Replies to post #72870 on Biotech Values

[randychub]

NVS might not be the only co. interested in IDIX.

LONDON, Feb 6 (Reuters) - GlaxoSmithKline Plc (GSK.L) has agreed to pay up to $450 million to access an experimental AIDS drug from Idenix Pharmaceuticals Inc (IDIX.O), the two companies said on Friday.

The deal underscores a drive by the world's second-biggest drugmaker to tap into promising science outside its own laboratories, a strategy highlighted by CEO Andrew Witty during a post-results presentation on Thursday.

-randy

[tony111]

I was hoping for a better upfront somewhere between 30-40M so the company would have more cash cushion till next year. I look forward for the data in EASL. Thanks for the reply DEW.